Merck Drug Shows Improved Odds for Melanoma Patients

Merck’s new cancer drug Keytruda improved the survival odds of patients with the skin cancer melanoma compared with Bristol-Myers Squibb’s Yervoy, in the first head-to-head study of a new wave of drugs that harness the body’s immune system to destroy tumors



from WSJ.com: US Business http://ift.tt/1IYO2yA

via IFTTT